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Abstract
Bcl11a is a transcription factor known to regulate lymphoid and erythroid development. Recent bioinformatic analysis of
global gene expression patterns has suggested a role for Bcl11a in the development of dendritic cell (DC) lineages. We
tested this hypothesis by analyzing the development of DC and other lineages in Bcl11a2/2 mice. We found that Bcl11a was
required for expression of IL-7 receptor (IL-7R) and Flt3 in early hematopoietic progenitor cells. In addition, we found
severely decreased numbers of plasmacytoid dendritic cells (pDCs) in Bcl11a2/2 fetal livers and in the bone marrow of
Bcl11a2/2 fetal liver chimeras. Moreover, Bcl11a2/2 cells showed severely impaired in vitro development of Flt3L-derived
pDCs and classical DCs (cDCs). In contrast, we found normal in vitro development of DCs from Bcl11a2/2 fetal liver cells
treated with GM-CSF. These results suggest that the persistent cDC development observed in Bcl11a2/2 fetal liver chimeras
reflects derivation from a Bcl11a- and Flt3-independent pathway in vivo.
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Introduction
Dendritic cells (DCs), comprising classical DCs (cDCs) and
plasmacytoid DCs (pDCs), develop from a common DC progen-
itor (CDP) residing in the bone marrow (BM); unlike myeloid
progenitors at earlier stages of development, CDPs have excluded
monocyte and macrophage potential but give rise to all DC subsets
at the clonal level [1–4]. Several transcription factors that act
broadly in hematopoiesis are known to regulate the development
of all DCs, including Ikaros [5,6], PU.1 [7,8], and Gfi1 [9].
Transcription factors that regulate specific subsets of DCs have
also been reported. For example, E2-2 is required for development
of pDCs [10], Batf3 for CD8+ cDCs [11], Irf8 for pDCs and CD8+
cDCs [12,13], and the NF-kB family member RelB for CD4+
cDCs [5,14,15].
A bioinformatic analysis of global gene expression patterns has
identified groups of transcription factors that may be involved in
fate decisions along the DC lineage [16]. Among genes that
increase in expression from the macrophage–DC progenitor
(MDP) to the CDP, those that do not increase in expression from
the MDP to the monocyte were labeled in that analysis as possible
promoters of DC commitment. Transcription factors identified by
these criteria include some previously associated only with pDC
development, including E2-2 and Spi-B [17,18], and some
previously associated only with cDCs, including Zbtb46 [19,20].
Other factors identified in this analysis include Irf8, Bcl11a, and
Runx2. Recently, it has been demonstrated in the setting of
competitive BM reconstitution that Irf8 promotes the development
of all DC subsets [21], even though Irf82/2 mice in other settings
do not show defects in CD4+ cDC development [12,13]. We
wondered, therefore, whether a similar early role in DC
development could be identified for another factor such as Bcl11a.
Bcl11a was first described as a gene located at a common
proviral integration site in BXH2 myeloid leukemias, and its
human ortholog was found to be a recurrent target of transloca-
tions in B cell malignancies [22,23]. This gene encodes a Kru¨ppel-
like zinc finger transcription factor expressed in neural and
lymphoid tissues that is essential for the development of B cells and
for thymocyte maturation [24]. In the erythroid lineage, BCL11A
acts in trans to silence the fetal hemoglobin locus in cooperation
with the transcription factor SOX6 [25,26]. Indeed, differences in
stage-specific expression between human BCL11A and mouse
Bcl11a account at least in part for interspecies differences in fetal
hemoglobin expression patterns [25].
Although Bcl11a has been recognized as a useful marker of
pDCs [27,28], its actual role in DC development remains
unreported. Thus, we sought to examine DC development in
the setting of Bcl11a deficiency in vivo and in vitro. We found that
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Bcl11a was required for normal expression of IL-7 receptor (IL-
7R) as well as Flt3 in early hematopoietic progenitors. In addition,
we observed a strict requirement for Bcl11a in pDC development
and found evidence for a Bcl11a-independent pathway of cDC
development in vivo.
Results
Bcl11a is Required for Development of CLPs and CDPs
During hematopoiesis, Bcl11a is expressed at similar levels in the
hematopoietic stem cell (HSC), multipotent progenitor (MPP),
common lymphoid progenitor (CLP), common myeloid progenitor
(CMP), and megakaryocyte–erythroid progenitor (MEP) [16]. To
study the function of Bcl11a in hematopoietic progenitors, we used
mice targeted for deletion of the first exon of Bcl11a [24]. Since
Bcl11a2/2 mice die in utero or perinatally, we compared
hematopoietic progenitor populations present in wild type (WT)
and Bcl11a2/2 fetal livers at embryonic day 14.5. First, we
analyzed development of Lin2Sca-1+c-Kit+ (LSK), CLP, granu-
locyte-macrophage progenitor (GMP), MEP, and CDP popula-
tions (Fig. 1). WT and Bcl11a2/2 fetal livers showed comparable
frequencies of GMPs and MEPs. However, Bcl11a2/2 fetal livers
showed a greater than twofold decrease in the frequency of LSK
cells and more marked decreases in frequencies of IL-7R+ CLPs
and Flt3+ CDPs relative to WT fetal livers (Fig. 1A, B); within the
LSK fraction, Bcl11a2/2 fetal livers showed defects in both
CD150 (Slamf1)+ and CD150– populations (Fig. 1C). One study
has demonstrated that a Sca-1loc-Kit+Flt3+CD150– population
with granulocyte and macrophage potential (SL-GMP) can be
identified which excludes mast cell potential [29]; GMPs in the
Bcl11a2/2 fetal liver, however, lacked Flt3 expression (data not
shown) and no SL-GMP population could be identified (Fig. 1D).
Next, we analyzed hematopoietic development in chimeras
produced by transferring WT or Bcl11a2/2 fetal liver cells into
lethally irradiated congenic recipient mice (Fig. 2). Four to six
weeks after transfer, donor-derived Bcl11a2/2 BM showed
decreased frequencies of LSK cells, CLPs, and CDPs but
comparable frequencies of GMPs and MEPs relative to donor-
derived WT BM (Fig. 2A, B); within the LSK fraction, donor-
derived Bcl11a2/2 BM showed a greater proportion of CD150+
cells than did donor-derived WT BM, corresponding to a decrease
in the overall frequency of the more differentiated CD150–
population (Fig. 2C). As in Bcl11a2/2 fetal livers, no SL-GMP
population could be identified in donor-derived Bcl11a2/2 BM
(Fig. 2D). In summary, the loss of Bcl11a in hematopoietic
progenitors resulted in impaired development of LSK cells as well
as a selective loss of CLPs and CDPs; these effects were observed
both in the fetal stage and in the adult chimera, demonstrating that
this factor is required in fetal and adult hematopoiesis.
Conceivably, the absence of IL-7R+ CLPs and Flt3+ CDPs in
Bcl11a2/2 fetal livers and BM could result from a requirement for
Bcl11a in the development of the CLP and CDP or from a more
restricted requirement for Bcl11a in the expression of IL-7R and
Flt3, the surface markers that identify these populations. In either
case, however, the loss of Bcl11a should result in DC defects
because Flt3 ligand (Flt3L) signaling is essential for DC develop-
ment in the steady state [30–32].
Bcl11a Regulates Expression of Il7r and Flt3
To identify Bcl11a target genes that explain its role in
hematopoietic progenitors, we compared global gene expression
by microarray for donor-derived WT and Bcl11a2/2 populations
isolated from chimeric BM (Fig. 3). Since we observed that IL-
7R- and Flt3-expressing populations were affected by the loss of
Bcl11a, we avoided the use of these surface markers in order to
allow for comparison of equivalent populations across genotypes.
Thus, we isolated multipotent progenitors (MPPs) as identified by
the lack of CD150 expression within the LSK fraction [33–35].
We also isolated GMPs from the same BM, since the size of this
population was unaffected by loss of Bcl11a.
We found that WT and Bcl11a2/2 GMPs were more similar to
each other in gene expression than WT and Bcl11a2/2 MPPs
were to each other (Fig. 3A). One hundred and thirty-four probe
sets showed a greater than twofold change in expression between
WT and Bcl11a2/2 GMPs. In contrast, 1020 probe sets showed a
greater than twofold change in expression between WT and
Bcl11a2/2 MPPs; of these, only 38 also show a greater than
twofold change between WT and Bcl11a2/2 GMPs (Fig. 3B).
These data suggest that GMP population size is unaffected by loss
of Bcl11a because this transcription factor regulates relatively few
genes in GMPs.
Since the loss of Bcl11a impaired development of CDPs but not
GMPs, we examined Bcl11a target genes which showed expression
patterns that distinguish DCs from monocytes and macrophages.
Thus, we compared the ratio of gene expression in CDPs relative
to monocytes against the ratio of gene expression in Bcl11a2/2
MPPs relative to WT MPPs (Fig. 3C). Of genes most highly
expressed in CDPs relative to monocytes, those most affected by
loss of Bcl11a included Flt3, Cnn3 (encoding calponin 3), Dntt
(encoding the template-independent DNA polymerase TdT), Il7r,
and Blnk (encoding B-cell linker protein, which links components
of B-cell receptor signaling). We also compared changes in gene
expression between WT and Bcl11a2/2 MPPs for members of the
core cDC transcriptional signature identified in a published
bioinformatic analysis [16] (Fig. 3D). Within this core signature,
we found only three genes–Ass1, Amica1, and Flt3–that showed a
greater than twofold decrease in expression in Bcl11a2/2 MPPs
relative to WT MPPs. Taken together, the decreased expression of
Flt3 and Il7r in Bcl11a2/2 MPPs suggests that Bcl11a may be
specifically required for the expression of these genes.
Bcl11a is Required for pDC but not cDC Development
in vivo
Next, we examined the development of mature hematopoietic
subsets in WT and Bcl11a2/2 fetal liver chimeras (Fig. 4). In
accordance with previous reports [24], we observed atrophic
thymi in Bcl11a2/2 chimeras (data not shown). In the BM, the size
of the donor-derived compartment was comparable in WT and
Bcl11a2/2 chimeras; in the spleen and skin-draining lymph nodes,
Bcl11a2/2 cells were somewhat impaired in their competition
against the residual host population (Fig. 4A). Within the donor-
derived compartment of the spleen, a profound defect in pDC
development was apparent in Bcl11a2/2 chimeras relative to WT
chimeras (Fig. 4B). In contrast, donor-derived cDCs were present
in Bcl11a2/2 chimeras with no significant decrease relative to WT
chimeras (Fig. 4C).
Among lymphoid subsets, donor-derived B cells, CD4 T cells,
CD8 T cells, and cd T cells were decreased in frequency by at least
tenfold in the spleens of Bcl11a2/2 chimeras as compared to WT
chimeras, consistent with previous reports [24], while NK cells
were decreased by slightly more than threefold (Fig. 5A). Among
myeloid subsets other than pDCs, donor-derived CD82 cDCs
showed a modest threefold decrease in the spleens of Bcl11a2/2
chimeras as compared to WT chimeras; other myeloid populations
examined, including CD8+ cDCs, were not decreased in frequency
(Fig. 5B). Thus, Bcl11a was strictly required for the development
of pDCs but not cDCs in vivo.
Bcl11a Controls pDC Development In Vivo
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Flt3-dependent, but not GM-CSF–dependent, DC
Development Requires Bcl11a in vitro
We compared the development of WT and Bcl11a2/2 cells
in vitro in response to treatment with Flt3L or granulocyte
macrophage colony-stimulating factor (GM-CSF) (Fig. 6). The
observation that Flt32/2 mice retain DC development [36]
suggests an alternative receptor for Flt3L or a Flt3L-independent
pathway for DC development. Thus, we supplied excess Flt3L or
GM-CSF to distinguish between these possibilities in the context of
Bcl11a deficiency. As expected, pDCs developed from WT fetal
liver cells (Fig. 6A) and from the donor-derived BM cells of WT
chimeras (Fig. 6B) in response to Flt3L treatment. In contrast,
pDCs developed in markedly decreased numbers from Bcl11a2/2
fetal liver cells and completely failed to develop from the donor-
derived BM cells of Bcl11a2/2 chimeras under these conditions
(Fig. 6A, B), demonstrating that Bcl11a is required for pDC
Figure 1. Bcl11a is required for development of lymphoid and DC progenitors in the fetus. (A) Flow cytometry analysis of progenitor
populations in WT and Bcl11a2/2 fetal livers dissected at embryonic day 14.5 (E14.5). Populations are gated as indicated; numbers represent the
percentage of cells within the histogram that lie in the indicated gate. Data are representative of two mice per group. (B) Progenitor populations in
WT and Bcl11a2/2 fetal livers at E14.5, analyzed by flow cytometry as in (A) and presented as a percentage of total fetal liver cells. Bars represent the
mean (6 SEM) of two mice per group. (C) CD150 (Slamf1) expression within the LSK fraction in WT and Bcl11a2/2 fetal livers at E14.5. (D) SL-GMPs in
WT and Bcl11a2/2 fetal livers at E14.5.
doi:10.1371/journal.pone.0064800.g001
Bcl11a Controls pDC Development In Vivo
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development in response to Flt3L both in vivo and in vitro. We also
examined cDC development from WT and Bcl11a2/2 fetal liver
cells in vitro in response to treatment with Flt3L or GM-CSF.
Flt3L-derived cDCs were markedly reduced in cultures of
Bcl11a2/2 fetal liver cells relative to cultures of WT fetal liver
cells (Fig. 6C, E). However, GM-CSF–derived DCs developed in
normal numbers from cultures of Bcl11a2/2 fetal liver cells relative
to cultures of WT fetal liver cells (Fig. 6D, F). These results
suggest that Flt3L cannot signal through an alternative receptor to
rescue cDC development in Bcl11a2/2 cells, but that an
alternative pathway of DC development may be mediated by
GM-CSF.
Figure 2. Bcl11a is required for development of lymphoid and DC progenitors in the adult. (A) Flow cytometry analysis of progenitor
populations in lethally irradiated congenic mice reconstituted with WT or Bcl11a2/2 fetal liver cells, analyzed four weeks after transplant. Data are
representative of three mice per group. (B) Progenitor populations in WT and Bcl11a2/2 fetal liver chimeras at four weeks after transplant, analyzed
by flow cytometry as in (A) and presented as a percentage of total BM cells. Bars represent the mean (6 SEM) of three mice per group. (C) CD150
(Slamf1) expression within the donor-derived LSK fraction in WT and Bcl11a2/2 fetal liver chimeras at four weeks after transplant. (D) SL-GMPs in WT
and Bcl11a2/2 fetal liver chimeras at four weeks after transplant.
doi:10.1371/journal.pone.0064800.g002
Bcl11a Controls pDC Development In Vivo
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Loss of Flt3L Results in Lineage-specific Defects in pDC
Development
Next, we examined the development of splenic pDCs in the
context of IL-7R or Flt3L deficiency. A previous study has
demonstrated that splenic pDCs in Il7r2/2 mice or Il72/2 mice
are decreased in absolute number when compared to WT controls
[37]. We found that splenic pDCs in Il7r2/2 mice were not
decreased in proportion to total splenocytes when compared to
WT controls matched for strain, age, and sex (Fig. 7A). This result
suggests that the hematopoietic defects in these mice may have
relatively few lineage-specific consequences for pDC development.
Previously, it has been found that Flt32/2 mice and Flt3l2/2
mice show defects in the development of pDCs [36,38].
Accordingly, and in contrast to our observations in Il7r2/2 mice,
we found that Flt3l2/2 mice showed a greater than fourfold
reduction in splenic pDC frequency as compared to WT littermate
controls (Fig. 7B), in addition to reductions in absolute spleen size
(data not shown).
Bcl11a is Required for Flt3 Expression in cDCs and Binds
the Flt3 Genomic Locus
Because we observed cDC development in Bcl11a2/2 chimeras,
we assessed whether these cells might express Flt3 in a Bcl11a-
independent manner; however, unlike WT cDCs in the BM,
Bcl11a2/2 cDCs in the same compartment showed no discernible
Flt3 expression by flow cytometry (Fig. 7C), again suggesting that
Figure 3. Bcl11a regulates the expression of Flt3 and Il7r. (A) Microarray analysis of sorted GMPs (left) and MPPs (right) from WT and Bcl11a2/2
fetal liver chimeras. (B) Shown is a Venn diagram of probe sets (excluding normalization controls) with a greater than twofold change in expression
between WT and Bcl11a2/2 MPPs. (C) Shown are log2-transformed ratios of gene expression in Bcl11a
2/2 MPPs relative to WT MPPs (x-axis) plotted
against log2-transformed ratios of gene expression in WT CDPs relative to WT monocytes (ImmGen; y-axis). For clarity, probe sets with less than
twofold changes in expression (log2-transformed ratios between 21 and 1) along either dimension are omitted (gray). (D) Shown is a heat map of
log2-transformed gene expression in WT and Bcl11a
2/2 GMPs and MPPs for probe sets that constitute an ImmGen core cDC signature. Highlighted
are genes that show a greater than twofold change in expression between WT and Bcl11a2/2 GMPs (red) or between WT and Bcl11a2/2 MPPs
(green).
doi:10.1371/journal.pone.0064800.g003
Bcl11a Controls pDC Development In Vivo
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a Flt3-independent pathway is instead responsible for their
development. Finally, to assay Bcl11a binding at the Flt3 locus,
we performed chromatin immunoprecipitation (ChIP) using
mouse pro-B cells. By quantitative real-time polymerase chain
reaction (qPCR), we detected an approximately threefold enrich-
ment at a region in the first intron of the Flt3 locus in DNA
precipitated using anti-Bcl11a antibody as compared to isotype
control (Fig. 7D).
Figure 4. Bcl11a is required in vivo for development of pDCs
but not cDCs. (A) Donor-derived (CD45.2+) chimerism in the BM,
spleen, and skin-draining lymph node (SLN) of WT and Bcl11a2/2 fetal
liver chimeras. Bars represent the mean (6 SEM) of three mice per
group. (B) Flow cytometry analysis of donor-derived pDCs in the spleen.
Data are representative of three mice per group. (C) Flow cytometry
analysis of donor-derived cDCs in the spleen. Data are representative of
three mice per group.
doi:10.1371/journal.pone.0064800.g004
Figure 5. Bcl11a deficiency in vivo impairs development of
lymphoid and myeloid populations. (A) Donor-derived lymphoid
populations in the spleen of WT and Bcl11a2/2 fetal liver chimeras,
analyzed by flow cytometry. Bars represent the mean (6 SEM) of three
mice per group. (B) Donor-derived myeloid populations in the spleen of
WT and Bcl11a2/2 fetal liver chimeras, analyzed by flow cytometry as in
Fig. 4. Bars represent the mean (6 SEM) of three mice per group.
doi:10.1371/journal.pone.0064800.g005
Bcl11a Controls pDC Development In Vivo
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In summary, our results document a strict requirement for
Bcl11a in pDC development both in vivo and in vitro; further, the
requirement for Bcl11a in cDC development may differ based on
the cytokine stimulus to which progenitors are exposed. The
actions of Bcl11a include regulation of Flt3 expression by direct
binding to the Flt3 locus, and Bcl11a is required for Flt3 expression
in DCs and their progenitors.
Figure 6. Bcl11a is required in vitro for development of Flt3L-derived pDCs and cDCs but not GM-CSF–derived cDCs. (A) Flow
cytometry analysis of pDCs in Flt3L cultures of fetal liver cells. Data are representative of three to four replicates over two experiments. (B) Flow
cytometry analysis of pDCs in Flt3L cultures of BM cells derived from fetal liver chimeras. Data are representative of three replicates. (C, D) Flow
cytometry analysis of Flt3L-derived cDCs (C) or GM-CSF-derived DCs (D) in cultures of fetal liver cells. Data are representative of three to four
replicates over two experiments. (E, F) Counts of total cells and indicated subsets in Flt3L cultures (E) or GM-CSF cultures (F) of fetal liver cells,
analyzed by flow cytometry as in (C) or (D), respectively. Bars represent the mean (6 SEM) of three to four replicates per group pooled from two
experiments.
doi:10.1371/journal.pone.0064800.g006
Bcl11a Controls pDC Development In Vivo
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Discussion
This study extends the known actions of Bcl1la in immune
lineage development and provides a mechanism for its effects.
Although Bcl11a has been recognized as a factor required for
normal lymphoid development [24], the basis for this requirement
has been unclear. It has been shown that Bcl11a acts upstream of
the B cell factors Ebf1 and Pax5 and that Il7r mRNA is not
expressed in Bcl11a2/2 fetal livers [24]. Lack of IL-7Ra or the
cytokine receptor common c chain (cc, encoded by Il2rg) severely
impairs T and B cell development [39–43]. In T cell development,
IL-7R signaling is thought to promote thymocyte survival, since
Bcl-2 rescues impaired T cell development in Il7r2/2 or Il2rg2/2
mice [44–48]. In B cell development, Bcl-2 does not rescue
development in the absence of IL-7R or cc [44–47,49], and IL-7R
signaling is thought to induce expression of the transcription factor
Ebf in the CLP [50–52].
Here, we demonstrate that Bcl11a is required for normal
expression of IL-7R as early as the CLP and we add the novel
observation that Bcl11a promotes the development of Flt3-
dependent lineages. Together, these actions provide a more
complete account for previously observed defects in lymphocyte
development in Bcl11a2/2 mice, since T cell potential is preserved
in IL-7–deficient CLPs in a Flt3L-dependent manner [53,54]. The
mechanisms by which Bcl11a deficiency impairs T and B cell
development, however, still remain incompletely explored. Con-
sistent with a previous report [24], we confirmed the presence of
residual T and B cells in the spleen of chimeras reconstituted with
Bcl11a2/2 fetal liver cells. By contrast, tamoxifen-induced deletion
of Bcl11a in chimeras that have been reconstituted with Rosa26-
CreERT2;Bcl11aflox/flox BM cells results in a more profound loss of
T and B cells [55]. Thus, synchronous deletion of Bcl11a within a
previously intact hematopoietic compartment produces a different
outcome than does sustained deficiency throughout hematopoiesis.
These results may point to a crucial lymphopoietic role for cells in
which Bcl11a is dispensable for survival but necessary for
development or maturation, or vice versa; these cells could include
HSCs, mature T and B cells, or even residual CLPs undetectable
due to a lack of IL-7R and Flt3 expression.
In line with a previous finding that E2-2 regulates Bcl11a
expression [18], we also document a strict requirement for Bcl11a
in the development of pDCs. The development of pDCs in vivo was
lost in Bcl11a2/2 fetal liver chimeras. In agreement, Flt3L cultures
of BM derived from these Bcl11a2/2 chimeras showed a complete
loss of pDC development in vitro. Because mature pDCs are short-
lived, non-proliferative, and continuously replenished from pro-
genitor populations [56,57], the nearly complete loss of this
population is most attributable to a developmental defect and not
merely to cell survival defects in mature pDCs. This interpretation
would be consistent with a finding that rescue of Bcl11a-deficient
progenitors from increased apoptosis by p53 deficiency is unable
to restore lymphoid potential [55].
Notably, however, in vitro development of cDCs was eliminated
in Flt3L cultures of Bcl11a2/2 fetal liver cells but was maintained
in GM-CSF cultures of Bcl11a2/2 fetal liver cells. Flt3L and GM-
CSF have distinct, non-redundant actions in supporting cDC
development [58,59]. The combined loss of Flt3L and GM-CSF
causes a more severe cDC deficiency than loss of Flt3L alone;
indeed, Flt3L-deficient mice retain an appreciable population of
Figure 7. Cytokine signaling in DC development and regulation by Bcl11a. (A) Flow cytometry analysis of pDCs in WT and Il7r2/2 spleens.
Data are representative of four mice per group over two experiments. (B) Flow cytometry analysis of pDCs in WT and Flt3l2/2 spleens. Data are
representative of three mice per group over two experiments. (C) Flow cytometry analysis of donor-derived cDCs in the spleen of WT and Bcl11a2/2
fetal liver chimeras, analyzed by flow cytometry as in Fig. 4. Data are representative of three mice per group. (D) Bcl11a binding in the Flt3 genomic
locus assayed by ChIP-qPCR. Data are represented as fold enrichment as compared to isotype control.
doi:10.1371/journal.pone.0064800.g007
Bcl11a Controls pDC Development In Vivo
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Flt3-expressing progenitors [38]. The maintenance of cDCs in
Bcl11a2/2 fetal liver chimeras suggests that these cells may rely on
a Bcl11a- and Flt3-independent pathway for their development,
survival, or expansion. Conditional knockout models would clarify
which of these alternatives underlie the observed phenotype in
Bcl11a2/2 mice. Since DCs developed normally in vitro from
Bcl11a2/2 progenitors treated with GM-CSF, it is possible that
Bcl11a2/2 cDCs in vivo indeed represent development from GM-
CSF–dependent progenitors, related perhaps to monocyte-derived
dendritic cell lineages [60].
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with recom-
mendations in the U.S. National Research Council Guide for the
Care and Use of Laboratory Animals. The protocol was approved by
the Washington University Animal Studies Committee
(#20090320).
Mice
C57BL/6, B6.SJL, Il72/2, and Il7r2/2 mice were purchased
from The Jackson Laboratory. Flt3l2/2 and Rag22/2 mice were
purchased from Taconic Farms. Flt3l2/2 mice were subsequently
crossed to Zbtb46gfp/gfp mice generated previously [19]; F2 offspring
were studied in the present experiments, with Zbtb46+/gfp;Flt3l+/+
or Zbtb46gfp/gfp;Flt3l+/+ mice used as WT littermate controls.
Bcl11a2/2 mice were obtained from Dr. Pentao Liu [24]. Mice
were bred and maintained in our specific pathogen free animal
facility at Washington University in St. Louis. Mice were sacrificed
by CO2 overdose followed by cervical dislocation.
Single-cell Suspensions of Fetal Liver
At embryonic day 14.5, fetal livers were mechanically dissoci-
ated with a syringe plunger and sterile 70-mm cell strainer (Fisher)
into IMDM +10% (v/v) FCS (I10F). For subsequent cell culture or
flow cytometry, red blood cells were lysed in ACK lysing buffer
before counting by Vi-CELL (Beckman Coulter).
Antibodies
The following antibodies were purchased from BD Biosciences:
FITC anti-CD3e (145-2C11), APC anti-CD4 (RM4-5), V450 anti-
CD4 (RM4-5), PerCP-Cy5.5 anti-CD8a (53-6.7), PerCP-Cy5.5
anti-CD11b (M1/70), APC anti-CD11c (HL3), APC anti-CD19
(1D3), PE-Cy7 anti-CD24 (M1/69), APC anti-CD25 (PC61),
FITC anti-CD45 (30-F11), APC anti-CD45.2 (104), APC-Cy7
anti-CD45.2 (104), PE anti-CD135 (A2F10.1), APC anti-CD172a
(P84), FITC anti-B220 (RA3-6B2), V500 anti-B220 (RA3-6B2),
PE anti-Gr-1 (RB6-8C5), V450 anti-Gr-1 (RB6-8C5), PerCP-
Cy5.5 anti-IgM (R6-60.2), PE-Cy7 anti-Ly-6A/E (Sca-1) (D7),
FITC anti-Ly-6C (AL-21), V450 anti-Ly-6C (AL-21), PE anti-Ly-
6G (1A8), PE anti-MHC II (I-A/I-E) (M5/114.15.2), PE anti-
TCRcd (GL3). The following antibodies were purchased from
eBioscience: APC-eFluor 780 anti-CD11c (N418), eFluor 450 anti-
CD11c (N418), PerCP-Cy5.5 anti-CD16/32 (93), APC-eFluor 780
anti-CD44 (IM7), biotin anti-CD45.1 (A20), PerCP-Cy5.5 anti-
CD45.1 (A20), Alexa Fluor 700 anti-CD45.2 (104), PE-Cy7 anti-
CD49b (DX5), PE anti-CD103 (2E7), APC-eFluor 780 anti-
CD117 (ACK2), PE-Cy7 anti-CD117 (2B8), FITC anti-CD127
(A7R34), APC anti-CD150 (mShad150), eFluor 450 anti-B220
(RA3-6B2), PE-Cy7 anti-B220 (RA3-6B2), APC anti-BST2
(eBio927), eFluor 450 anti-BST2 (eBio927), FITC anti-F4/80
(BM8), PE anti-IgD (41239), eFluor 450 anti-MHC II (I-A/I-E)
(M5/114.15.2), eFluor 450 anti-NKp46 (29A1.4), FITC anti-
Siglec-H (eBio440C). The following antibodies were purchased
from Caltag: FITC anti-CD8a (5H10), PE anti-B220 (RA3-6B2).
Qdot 605 streptavidin was purchased from Invitrogen and V500
streptavidin was purchased from BD Biosciences.
Flow Cytometry and Sorting
Staining was performed at 4uC in the presence of Fc block
(clone 2.4G2, BD Biosciences or BioXCell) in FACS buffer (DPBS
+0.5% BSA +2 mM EDTA). Cells were analyzed using a
FACSCanto II (BD Biosciences) or sorted using a FACSAria
(BD Biosciences); data were visualized using FlowJo software
(TreeStar).
Cell Cultures
Cells were diluted to 26106 cells/ml in I10F +20 ng/ml Flt3L
or GM-CSF, cultured in 12-well plates for 10 d (Flt3L) or 7 d
(GM-CSF), then analyzed by flow cytometry.
Chimeras
B6.SJL mice were lethally irradiated (1200 rad) and injected
intraorbitally with 46106 fetal liver cells isolated from WT or
Bcl11a2/2 fetuses. After 4 or 6 weeks, BM was isolated by grinding
and Histopaque-1119 (Sigma-Aldrich) centrifugation and either
sorted by flow cytometry or cultured. From these mice, thymi were
minced and digested in 250 mg/ml collagenase B (Roche) and
30 U/ml DNase I (Sigma-Aldrich) and analyzed by flow
cytometry.
Microarray Analysis
MPP and GMP populations were sorted from fetal liver
chimeras and pooled by donor genotype. RNA was isolated using
an RNAqueous-Micro Kit (Ambion) and submitted for amplifica-
tion, labeling and hybridization. Expression values were analyzed
after RMA quantile normalization using ArrayStar software
(DNASTAR). Data were deposited in the Gene Expression
Omnibus (GEO) repository under accession no. GSE46270.
ChIP-qPCR
Pro-B cell cultures were established using Rag22/2 BM isolated
by flushing and resuspended in I10F +5 ng/ml IL-7. Chromatin
was prepared from 16107 cultured pro-B cells sonicated using a
Bioruptor (Diagenode), immunoprecipitation was performed with
a rabbit polyclonal anti-Bcl11a antibody (NB600-261, Novus
Biologicals) or control rabbit IgG, and qPCR analysis was carried
out using SYBR Green-based detection and the following
previously published primers [61]: Flt3 control forward, 59-
TTTGCACTCGTAGCAAATGG-39; Flt3 control reverse, 59-
GTTCAGCTGCCAAAGAGAGG-39; Flt3 promoter forward, 59-
GTTCAGCTGCCAAAGAGAGG-39; Flt3 promoter reverse, 59-
CGTCACTGACCACAGATTCC-39; Flt3 intron forward, 59-
AAAAGAGGAACTATTGGTATTTCG-39; Flt3 intron reverse,
59-TGACAGTAGTGAAAACACACACACA-39.
Statistics
Statistical differences were identified using Prism 6 (GraphPad)
by multiple unpaired Student’s t tests, controlling the false
discovery rate (Q) by the method of Benjamini and Hochberg. *,
Q=0.05; **, Q= 0.01.
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